News

Novo Nordisk to present phase 3 trials across hemophilia portfolio, reinforcing commitment to research in rare blood disorders, at ISTH 2025
Novo Nordisk today announced that new hemophilia data will be presented at the upcoming International Society on Thrombosis ...